Aclaris Therapeutics (ACRS) Gross Margin: 2017-2025
Historic Gross Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to 83.69%.
- Aclaris Therapeutics' Gross Margin fell 126.00% to 83.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 85.62%, marking a year-over-year decrease of 400.00%. This contributed to the annual value of 85.09% for FY2024, which is 396.00% down from last year.
- Per Aclaris Therapeutics' latest filing, its Gross Margin stood at 83.69% for Q3 2025, which was up 17.85% from 71.02% recorded in Q2 2025.
- Aclaris Therapeutics' 5-year Gross Margin high stood at 95.87% for Q4 2023, and its period low was 20.51% during Q1 2022.
- Over the past 3 years, Aclaris Therapeutics' median Gross Margin value was 77.44% (recorded in 2024), while the average stood at 76.36%.
- Examining YoY changes over the last 5 years, Aclaris Therapeutics' Gross Margin showed a top increase of 6,524bps in 2022 and a maximum decrease of 1,185bps in 2022.
- Aclaris Therapeutics' Gross Margin (Quarterly) stood at 23.45% in 2021, then soared by 6,524bps to 88.69% in 2022, then soared by 719bps to 95.87% in 2023, then tumbled by 353bps to 92.35% in 2024, then slumped by 126bps to 83.69% in 2025.
- Its Gross Margin was 83.69% in Q3 2025, compared to 71.02% in Q2 2025 and 65.22% in Q1 2025.